引用文献

1)津谷喜一郎(編). くすりギャップ:世界の医薬品問題の解決を目指して. ライフサイエンス出版; 2006.

2)Wardell WM. Introduction of new therapeutic drugs in the United States and Great Britain: an international comparison. Clin Pharmacol Ther 1973; 14: 773−90.

3)Wardell WM. The drug lag revisited: comparison by therapeutic area of patterns of drugs marketed in the United States and Great Britain from 1972 through 1976. Clin Pharmacol Ther 1978; 24: 499−524.

4)Andersson F. The drug lag issue: the debate seen from an international perspective. Int J Health Ser 1992; 22(1): 53−72.

5)Parker J. Who has a drug lag?. J Soc Admin Pharm 1989; 6: 138−52.

6)Parker J. Who has a drug lag?. Managerial and Decision Economics. 1989; 10: 299−309.

7)Keitin K, Mattison N, Northington N, Lasagna L. The drug lag: an update of new drug introductions in the United States and in the United Kingdom, 1977 through 1987. Clin Pharmacol Ther 1989; 46: 121−38.

8)Danzon PM, Wang YR, Wang L. The impact of price regulation on the launch delay of new drugs-evidence from twenty-five major markets in the 1990s. Health Econo 2005; 14: 269−92.

9)島谷克義, 須藤隆夫. 開発戦略における日本の課題. 医療と社会 2005; 15(1):43−50.
Available from URL:http://www.iken.org/activity/paper/past/h17/pdf/15-1-6.pdf[Accessed April 10, 2008]

10)福原浩行. 医薬品の世界初上市から各国における上市までの期間:日本の医薬品へのアクセス改善に向けて. 医薬産業政策研究所リサーチペーパー・シリーズNo.31. 2006.
Available from URL:http://www.jpma.or.jp/opir/research/article31.html[Accessed May 30, 2006]

11)安田邦章, 小野俊介. 日本における新医薬品の承認審査期間:2007年度調査. 医薬産業政策研究所リサーチペーパー・シリーズNo.37. 2007.
Available from URL: http://www.jpma.or.jp/opir/research/ article37.html [Accessed Jan. 27, 2008]

12)厚生労働省. 第1回「有効で安全な医薬品を迅速に提供するための検討会」資料3.
Available from URL:http://www.mhlw.go.jp/shingi/2006/10/s1030-8.html [Accessed Otc.10, 2006]

13)Tsuji K, Tsutani K. Personal imports of drugs to Japan in 2005: an analysis of import certificates. J Clin Pharm Ther 2008; 33(5): 545−52. 

14)厚生労働省. 未承認薬使用問題検討会議.
Available from URL:http://www.mhlw.go.jp/shingi/other.html#iyaku [Accessed Oct.10, 2006]

15)文部科学省・厚生労働省. 全国治験活性化3ヵ年計画. 文部科学省・厚生労働省; 2003.
Available from URL:http://www.mhlw.go.jp/shingi/2005/06/dl/s0630-7n.pdf [Accessed Oct.10, 2006]

16)厚生労働省. 治験のあり方に関する検討会.
Available from URL: http://www.mhlw.go.jp/shingi/other.html#iyaku[Accessed Jan.20, 2007]

17)文部科学省・厚生労働省. 新たな治験活性化5ヵ年計画. 文部科学省・厚生労働省; 2007.
Available from URL:http://www.mhlw.go.jp/shingi/2007/03/s0330-5.html [Accessed Jan.20, 2007]

18)厚生労働省. 有効で安全な医薬品を迅速に提供するための検討会.
Available from URL:http://www.mhlw.go.jp/shingi/other.html#iyaku [Accessed Jan. 20, 2007]

19)文部科学省・厚生労働省・経済産業省. 革新的医薬品・医療機器創出のための5ヵ年戦略. 文部科学省・厚生労働省・経済産業省; 2007.
Available from URL:http://www.mhlw.go.jp/houdou/2007/04/h0427-3.html [Accessed May 10, 2007]

20)Anderson TM. Introduction to multiple statistical analysis. John Wiley & Sons; 1958.

21)厚生労働省審査管理課長. HIV感染症治療薬の製造又は輸入承認申請について(医薬審1015号). 平成10年11月12日.

22)安田邦章, 小野俊介. 日本における新医薬品の開発期間:臨床開発期間と承認審査期間. 医薬産業政策研究所リサーチペーパー・シリーズNo.42. 2008.
Available from URL:http://www.jpma.or.jp/opir/research/article42.html[Accessed Jan. 27, 2009]

23)Tsuji K, Tsutani K. Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations. Eur J Pharm Biopharm 2008; 68(3): 496−502.

24)Tsuji K, Tsutani K. Follow the leader. Nature 2008; 453(7197): 851−2.

25)Oxfam International. Ending the R&D Crisis in Public Health: promoting pro-poor medical innovation. Oxfam Briefing Paper 122. 2008.
Available from URL:http://www.oxfam.org/files/bp122-randd-crisis-public-health.pdf [Accessed Feb. 23, 2009]

26)Drugs for Neglected Diseases.
Available from URL:http://www.dndi.org/[Accessed Feb.23, 2009]

27)Global Forum for Health Research.
Available from URL:http://www.globalforumhealth.org/Site/000__Home.php [Accessed Feb.27, 2009]

28)FDA. Amendment to the Food and Drug Administration Revitalization Act. 2007.
Available from URL:http://www.fda.gov/oc/initiatives/HR3580.pdf [Accessed Feb. 23, 2009]

29)FDA. New drug, antibiotic, and biological drug product regulations; accelerated approval. Federal Register 1992; 57(239): 58942−60. Available from URL:http://www.fda.gov/cder/guidance/append4.pdf [Accessed May 10, 2007]

30)EMEA. Guideline of procedures for the granting of a marketing authorization under exceptional circumstances, pursuant to Article 14(8) of regulation (EC) No 726/2004. London: 2005. Available from URL: http://www.emea.europa.eu/pdfs/human/euleg/35798105en.pdf[Accessed May 10, 2007]

31)EMEA. Guideline of the scientific application and the practical arrangements necessary to implement commission regulation (EU) No 507/2006 on the conditional marketing authorization for medicinal products for human use falling within the scope of Regulation (EC) no 726/2004. London; 2006.
Available from URL:http://www.emea.europa.eu/pdfs/human/regaffair/50995106en.pdf [Accessed May 10, 2007]

32)FDA. Orphan Drug Act (as amended) Available fromURL:http://www.fda.gov/orphan/oda.htm[Accessed Dec. 1, 2006]

33)EMEA. Orphan drugs and rare diseases at a glance. London; 2007.
Available from URL:http://www.emea.europa.eu/pdfs/human/comp/29007207en.pdf [Accessed Dec. 1, 2006]

34)EMEA. Committee for orphan medicinal products Rules of procedure. London; 2007.
Available from URL:http://www.emea.europa.eu/pdfs/human/comp/821200en.pdf [Accessed Dec. 1, 2006]

35)European Commission. Guideline on the format and content of applications for designation as orphan medicinal products and the transfer of designations from one sponsor to another, 9 July 2007. Brussels; 2007.

Available from URL:http://www.emea.europa.eu/pdfs/human/
comp/628300en.pdf [Accessed Dec.1, 2006]

 

36)医薬基盤研究所. 稀少疾病用医薬品開発振興業務.
Available from URL:http://www.nibio.go.jp/shinko/orphan. html[Accessed Dec.10, 2006]

37)白神誠, 中井清人. オーファンドラッグ開発の現状の分析. 臨床薬理 1999; 30(4): 681−701.

38)辻香織. 未承認薬使用に関するヨーロッパ各国の制度. 医療と社会 2008; 18(2): 243−56.